Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CollPlant Biotechnologies is a biotechnology business based in the US. CollPlant Biotechnologies stocks (CLGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.75 – a decrease of 5.33% over the previous week. CollPlant Biotechnologies employs 52 staff and has a trailing 12-month revenue of around $19.9 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Since the stock market crash in March caused by coronavirus, CollPlant Biotechnologies's stock price has had significant positive movement.
Its last market close was $16, which is 14.38% up on its pre-crash value of $13.6996 and 97.04% up on the lowest point reached during the March crash when the stocks fell as low as $8.12.
If you had bought $1,000 worth of CollPlant Biotechnologies stocks at the start of February 2020, those stocks would have been worth $774.97 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,493.92.
|Latest market close||$16|
|52-week range||$6.185 - $24.26|
|50-day moving average||$17.7026|
|200-day moving average||$16.3601|
|Wall St. target price||$23|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.505|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-09-15)||-5.83%|
|1 month (2021-08-20)||-4.31%|
|3 months (2021-06-22)||-22.37%|
|6 months (2021-03-22)||28.10%|
|1 year (2020-09-22)||94.53%|
|2 years (2019-09-19)||299.00%|
|3 years (2018-09-21)||213.73%|
Valuing CollPlant Biotechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CollPlant Biotechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CollPlant Biotechnologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, CollPlant Biotechnologies stocks trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.
CollPlant Biotechnologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$6.1 million.
The EBITDA is a measure of a CollPlant Biotechnologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$19.9 million|
|Operating margin TTM||27.11%|
|Gross profit TTM||USD$3.1 million|
|Return on assets TTM||10.22%|
|Return on equity TTM||17.69%|
|Market capitalisation||USD$172.6 million|
TTM: trailing 12 months
There are currently 13,120 CollPlant Biotechnologies stocks held short by investors – that's known as CollPlant Biotechnologies's "short interest". This figure is 25.1% down from 17,528 last month.
There are a few different ways that this level of interest in shorting CollPlant Biotechnologies stocks can be evaluated.
CollPlant Biotechnologies's "short interest ratio" (SIR) is the quantity of CollPlant Biotechnologies stocks currently shorted divided by the average quantity of CollPlant Biotechnologies stocks traded daily (recently around 18742.857142857). CollPlant Biotechnologies's SIR currently stands at 0.7. In other words for every 100,000 CollPlant Biotechnologies stocks traded daily on the market, roughly 700 stocks are currently held short.
However CollPlant Biotechnologies's short interest can also be evaluated against the total number of CollPlant Biotechnologies stocks, or, against the total number of tradable CollPlant Biotechnologies stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CollPlant Biotechnologies's short interest could be expressed as 0% of the outstanding stocks (for every 100,000 CollPlant Biotechnologies stocks in existence, roughly 0 stocks are currently held short) or 0.0013% of the tradable stocks (for every 100,000 tradable CollPlant Biotechnologies stocks, roughly 1 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against CollPlant Biotechnologies.
Find out more about how you can short CollPlant Biotechnologies stock.
We're not expecting CollPlant Biotechnologies to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
CollPlant Biotechnologies stocks were split on a 2:3 basis on 21 November 2016. So if you had owned 3 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your CollPlant Biotechnologies stocks – just the quantity. However, indirectly, the new 50% higher stock price could have impacted the market appetite for CollPlant Biotechnologies stocks which in turn could have impacted CollPlant Biotechnologies's stock price.
Over the last 12 months, CollPlant Biotechnologies's stocks have ranged in value from as little as $6.185 up to $24.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while CollPlant Biotechnologies's is 0.7762. This would suggest that CollPlant Biotechnologies's stocks are less volatile than average (for this exchange).
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has a co-development agreement with 3D Systems Corporation for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Everything we know about the Adtalem Global Education IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.